- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02762318
Identification and Characterization of Bone-related Genetic Variants in Families
Study Overview
Detailed Description
To identify novel genetic variants causing skeletal dysplasia in Qatari populations and to additionally develop an understanding of how those variants influence skeletal biology at a molecular and cellular level.
Achieving this goal will be split into two aims:
- Aim 1: Perform a clinical characterization of a study group of patients with various forms of skeletal dysplasia seen in pediatric orthopedics clinic at Hamad Medical center, HMC. This will be followed by whole exome or genome sequencing and analysis to search for novel pathogenic variants responsible for the clinical presentation of these patients
- Aim 2: The genes and variants identified in Aim 1 will be characterized to determine their effects on osteoblast and chondrocyte differentiation and function.
All the subjects will be recruited from the pool of patients seen by the Pediatric Orthopedic Consultants at the Bone and Joint Institute. Subjects will be coming to the clinic for their standard care. They will be identified during that visit as candidates for the study. They will then be told about the study by their physicians. If a patient is interested in participation, the physician will introduce the CRC to him/her who will proceed with the consent process.
Consenting and the study procedures might be performed during that same visit if time allows, or in a new scheduled visit arranged at that time.
This research will also involve a pedigree creation. Secondary subjects (family members or relatives) will be told about the study by the research subject. The secondary subject will be able to read a copy of the consent form, think of his participation, and if interested they will be told to contact the Investigators. A suitable time will then be arranged, by an appropriate member of the research team, for the secondary subject to visit the clinic in order to proceed with the consent process and the study procedures.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Doha, Qatar
- Hamad Medical Corporation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All included individuals must provide informed consent
- Patients identified to have a skeletal dysplasia
- All ethnic backgrounds are acceptable
- Disease must be genetic with no evident environmental cause.
Evidence of Mendelian Transmission determined by fulfilling one of the following criteria:
- Multiple affected family members (at least first-degree relative with disease)
- History of consanguinity
- Severe disease in newborn in the absence of family history
- Syndromic disease in single individuals
- Congenital abnormality affecting major organ system(s)
- Mendelianized extremes of common disease (e.g. bilateral developmental dysplasia of the hip)
- All ages will be included
- Rare diseases or rare forms of known diseases
- Unaffected family members or relatives of the individual with the primary syndrome
Exclusion Criteria:
- Individuals who do not consent will not be included
- Individuals for which a molecular diagnosis has already been established by alternative method (e.g. karyotype or known gene mutation)
- Diseases for which an environmental factor is most likely the cause (e.g. Traumatic bone injury or Rickets)
- Diseases of which late age of onset rule out Mendelian transmission
- Common Diseases for which late age of onset rule out Mendelian transmission (e.g.Osteoporosis)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical assessement of a study group of patients with various forms of skeletal dysplasia, followed by identification of novel pathogenic variants using whole exome/genome sequencing.
Time Frame: 2-3 years
|
Patients will be selected for the study and will undergo: Phenotyping by a combination of clinical history taking and examination, determination of bone mass, laboratory studies, Full exome sequencing Lastly, the variants present in each exome will be determined, and these variants will be classified according to their likelihood of being pathogenic. |
2-3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical and cellular characterization of the putative causative genes.
Time Frame: 1-2 year
|
Chondrocytes or osteoblasts will be used to measure the following: Putative gene expression in the skeletal system, How they influence osteoblast and chondrocyte differentiation how they alter the activity of the key molecular pathways governing the activity of osteoblasts and chondrocytes, |
1-2 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ronald Crystal, MD, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-00098
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skeletal Dysplasia
-
Karolinska InstitutetKarolinska University Hospital; Göteborg UniversityRecruitingSkeletal Dysplasia | Skeletal Disorder | Genetic Skeletal Diseases | Molecular CausesSweden
-
National Human Genome Research Institute (NHGRI)CompletedDwarfism | Developmental Bone Disease | Skeletal DysplasiasUnited States
-
Democritus University of ThraceCompletedSkeletal Muscle Performance | Skeletal Muscle Damage | Intgracellular Signaling in Skeletal Muscle | Inflammatory StatusGreece
-
University of BathUniversity of BristolRecruiting
-
Boston Children's HospitalJohns Hopkins University; University of Florida; National Institute for Biomedical...Completed
-
Cairo UniversityEnrolling by invitationSkeletal MaturationEgypt
-
AdventHealth Translational Research InstituteActive, not recruiting
-
University of ThessalyCompletedSkeletal Muscle Performance | Skeletal Muscle Damage | Exercise-induced Aseptic Inflammation | Intracellular Signaling in Skeletal Muscle | Proteasome ActivationGreece
-
Morten Hostrup, PhDNot yet recruitingSkeletal Muscle Physiology
-
Fujian Shengdi Pharmaceutical Co., Ltd.CompletedSkeletal Muscle RelaxationChina
Clinical Trials on Samples With DNA
-
Rennes University HospitalCompletedRare Iron OverlaodsFrance
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Sunnybrook Health Sciences CentreCompleted
-
Rigshospitalet, DenmarkCompleted
-
Assiut UniversityUnknownPrimary Immune Thrombocytopenia
-
IRCCS Eugenio MedeaMinistry of Health, ItalyCompletedA Multi-domain Approach for the Characterization and Early Diagnosis of Neurodevelopmental DisordersNeurodevelopmental DisordersItaly
-
Barzilai Medical CenterUnknownOral Squamous Cell Carcinoma | Medication Related Osteonecrosis of the Jaw | Oral Epithelial DysplasiaIsrael
-
University Hospital, ToulouseCompleted
-
University of ChicagoNational Institutes of Health (NIH); American Society of Clinical OncologyCompleted
-
Assistance Publique - Hôpitaux de ParisSociété ADEMTECH SACompletedInvasive Aspergillosis in Patients With Onco-haematological DiseasesFrance